Inclusion Criteria:
For the two retrospective cohorts:
  1. All patients that older than 18 treated for localized adenocarcinoma of the prostate between 2000 and 2017 with either radical prostatectomy or radiotherapy
  2. All treated patients had a rising post-treatment PSA, with at least one post-treatment free PSA blood test.
For the biobank validation cohort:
1. All patients treated with radical prostatectomy for localized prostate cancer between 2000 and 2017 who had biobank samples taken when developing biochemical recurrence.
Exclusion Criteria:
  1. Patients that were younger than 18,
  2. Patients with prostate cancer other than adenocarcinoma, such as small cell and neuroendocrine cancer
  3. Patients with prostate adenocarcinoma that did not develop biochemical recurrence.
  4. In the retrospective cohorts - patients that did not have at least one post-treatment free PSA blood test.